Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx
→ San Diego-based Imprimis has set up a new subsidiary to pursue the development of new drugs for eye diseases. And the company has tapped Kamran Hosseini to run the operation — Surface Pharmaceuticals — as the CEO.
→ The Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation are helping fund a new combination therapy for Alzheimer’s by Amylyx Pharmaceuticals. Their $1.85 million grant will support a small Phase II study with 50 patients, who will be treated with AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid.
→ Framingham, MA-based Alzheon says that it has gained the FDA’s fast track designation for the Alzheimer’s drug ALZ-801.